Immunotherapy

Mankind Pharma Ltd and Innovent Biologics on Thursday announced a partnership to exclusively license and commercialise innovative immunotherapy drug Sintilimab, used in the treatment of cancer, in the Indian market. This strategic collaboration aims to address the critical challenges in cancer treatment and improve patient access to innovative therapeutic options in the region, the companies said in a joint statement. Marketed as TYVYT (sintilimab injection) in China, Sintilimab is co-developed by Innovent and Eli Lilly. "Sintilimab is not approved in India. Early next year, we will be filing for its regulatory approval in India and complete all mandatory regulatory processes, including the conducting of a phase 3 clinical trial by Mankind Pharma for its successful approval in India once we receive the permission from the regulator to conduct such clinical trials," a Mankind Pharma spokesperson said. Under the agreement with Innovent, Mankind Pharma will have exclusive rights to ..

This works because cancers have fooled the body by using its own natural safety switches, or checkpoints

ImmunoACT, backed by Laurus Labs is testing their cancer product

Some oncologists choose not to mention immunotherapy to dying patients, arguing that scientists first must gather rigorous evidence about the benefits and pitfalls

Due to this trial, lesser insulin is needed to control people's blood glucose levels

With promising results, such new weapons are providing hope that cancer can ultimately be defeated